What specific areas of research meet the criteria for ASPIRE Cardiovascular research funding?

What areas of research meet the criteria for ASPIRE Cardiovascular research funding?
Specific scientific questions of interest are those bringing new insights into and advancing the understanding of the role of the PCSK9 protein/gene in health and disease. Projects that offer novel mechanistic insights would be welcomed.

Pre-identified research themes eligible for this research award program include:


  • Pathophysiology of non-diabetic or diabetic dyslipidemia and its relation to atherosclerotic vascular disease, including genetic, transcriptomic, metabolomic, lipidomic, proteomic, and clinical aspects
  • Lipoprotein particles, cellular lipoprotein receptors, and lipid homeostasis
  • Role of PCSK9 in:
    – Lipoprotein (a) metabolism
    – Tumorigenesis
    – Immune system
    – Infectious diseases
    – Vascular biology
  • Pathophysiology of cardiovascular diseases other than atherosclerosis (e.g., vein graft failure, thrombosis, valvular heart disease, stroke)
  • Non-lipid/lipoprotein effects of PCSK9 (e.g., role of PCSK9 in the central nervous system, intestine, pancreas, adrenals, adipose tissue, kidneys, gonads, etc.)
  • Biochemistry of PCSK9 (structural biology and mechanistic implications)
  • Identification of the unmet needs and/or residual risk in high risk secondary/primary prevention patients that may be addressed by PCSK9 inhibitors (i.e., retrospective database analyses, cohort studies utilizing existing populations, etc.). Such patients will be receiving lipid-lowering therapy in accordance with optimal current standards of care.

The following types of research projects are considered in scope and will be eligible for this program:


  • Basic/pre-clinical/clinical science (i.e., animal models, in vivo/in vitro studies)
  • Outcomes/epidemiological research to understand the unmet needs and/or residual risk in high risk secondary/primary prevention patients that may be addressed by PCSK9 inhibitors (i.e., retrospective database analyses, cohort studies utilizing existing populations, etc.). Such patients will be receiving lipid-lowering therapy in accordance with optimal current standards of care.(top)

FAQ Category:

FAQ Tag: 
excludedareas